The Efficacy of Potassium-competitive Acid Blocker in Patients With Laryngopharyngeal Reflux Disease

Laryngopharyngeal Reflux Disease Clinical Trial

Official title: The Efficacy of Potassium-competitive Acid Blocker (P-CAB) in Patients With Laryngopharyngeal Reflux Disease: a Double- Blind, Randomized, Placebo-controlled Pilot Study

Status Completed

Clinical Trial Summary

Background/Aims: Tegoprazan is a novel potassium-competitive acid blocker that has a fast onset of action and can control gastric pH for a prolonged period, which could offer clinical benefit in acid-related disorders. The investigators aimed to evaluate whether tegoprazan would be more effective in controlling symptoms than placebo in patients with laryngopharyngeal reflux disease (LPRD). Methods: This double-blind, randomized, placebo-controlled trial randomly assigned 35 patients suffering LPRD symptom to two groups: Tegoprazan50mg once daily and placebo. The primary end point was complete resolution rate of LPRD symptoms after 8-week medication, and the secondary endpoints were complete resolution rate of LPRD symptoms after 4-week medication, change of reflux symptom index (RSI) and reflux finding score (RFS) from baseline at 4- and 8-week medication.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Gastroesophageal Reflux
• Laryngopharyngeal Reflux
• Laryngopharyngeal Reflux Disease

• NCT number: NCT05871398
• Study type: Interventional
• Source: Pusan National University Hospital
• Status: Completed
• Phase: Phase 3
• Start date: October 1, 2019
• Completion date: February 28, 2023